Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Erythromycin is the drug of choice for treatment of Mycoplasma pneumoniae infections due to its susceptibility to low levels of this antibiotic. After exposure of susceptible strains to erythromycin in vitro and in vivo, mutants resistant to erythromycin and other macrolides were isolated. Their phe...

Deskribapen osoa

Xehetasun bibliografikoak

Argitaratua izan da:	Antimicrob Agents Chemother
Egile Nagusiak:	Lucier, T S, Heitzman, K, Liu, S K, Hu, P C
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology (ASM) 1995
Gaiak:	Research Article
Sarrera elektronikoa:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163027/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8593017/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.12.2770
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!